Financings in Brief: Imatron
This article was originally published in The Gray Sheet
Imatron: Completes $16 mil. private placement, funds from which will go to its HeartScan Imaging Inc. subsidiary, which provides coronary artery disease risk assessment using Imatron's Ultrafast CT scanner. Proceeds will allow HeartScan to "implement its plan for accelerating the opening of new centers" and "will allow us to establish HeartScan as a separate business which we expect will provide Imatron with a very strong continuing source of orders for our Ultrafast CT scanners as well as continued significant participation in HeartScan's service revenue stream," Imatron says. Investors in the placement include: SC Fundamental Value Fund, Cramer Rosenthal McGlynn, and Gruber & McBaine...
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.